What is Noble Financial’s Forecast for GYRE FY2025 Earnings?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) – Analysts at Noble Financial boosted their FY2025 earnings estimates for Gyre Therapeutics in a report issued on Monday, November 10th. Noble Financial analyst R. Leboyer now expects that the company will earn $0.22 per share for the year, up from their prior forecast of $0.09. Noble Financial also issued estimates for Gyre Therapeutics’ Q4 2025 earnings at $0.06 EPS.

Gyre Therapeutics (NASDAQ:GYRE) last announced its earnings results on Monday, August 11th. The company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The company had revenue of $26.77 million for the quarter, compared to analysts’ expectations of $30.80 million. Gyre Therapeutics had a net margin of 4.08% and a return on equity of 7.67%.

A number of other research analysts also recently weighed in on the company. HC Wainwright began coverage on Gyre Therapeutics in a report on Tuesday, August 26th. They issued a “buy” rating and a $18.00 target price on the stock. Jefferies Financial Group assumed coverage on shares of Gyre Therapeutics in a research note on Friday, October 10th. They issued a “buy” rating and a $16.00 price objective on the stock. Weiss Ratings restated a “sell (d)” rating on shares of Gyre Therapeutics in a research report on Wednesday, October 8th. Finally, Zacks Research downgraded shares of Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Thursday, October 16th. Three analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $17.00.

Gyre Therapeutics Price Performance

GYRE stock opened at $8.01 on Wednesday. Gyre Therapeutics has a 1 year low of $6.11 and a 1 year high of $19.00. The company has a market cap of $771.47 million, a P/E ratio of 801.80 and a beta of 1.88. The stock’s fifty day moving average price is $7.73 and its 200-day moving average price is $8.11.

Institutional Investors Weigh In On Gyre Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its holdings in Gyre Therapeutics by 40.4% during the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock valued at $84,000 after purchasing an additional 1,996 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Gyre Therapeutics by 18.7% during the 1st quarter. Bank of New York Mellon Corp now owns 16,492 shares of the company’s stock valued at $127,000 after purchasing an additional 2,596 shares during the period. SBI Securities Co. Ltd. lifted its stake in shares of Gyre Therapeutics by 22.1% during the 1st quarter. SBI Securities Co. Ltd. now owns 123,629 shares of the company’s stock valued at $954,000 after buying an additional 22,390 shares in the last quarter. American Century Companies Inc. purchased a new position in shares of Gyre Therapeutics during the 1st quarter valued at $184,000. Finally, Advantage Alpha Capital Partners LP boosted its holdings in Gyre Therapeutics by 54.0% in the 1st quarter. Advantage Alpha Capital Partners LP now owns 13,663 shares of the company’s stock worth $105,000 after buying an additional 4,790 shares during the period. Institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.